Insilico Medicine (03696) rose more than 6% in Hong Kong trading. At the time of writing, the stock was up 6.74% to HK$64.9, with a turnover of HK$131 million. The increase follows recent company developments in its AI-powered early-stage drug discovery platform. On April 20, Insilico announced progress in its unified AI framework for drug target discovery, integrating its Target Identification Pro (TargetPro) with the Target Identification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early drug research. A recent study published in Scientific Reports indicated that the framework delivered outstanding results in both benchmark evaluations and real-world target discovery workflows, reinforcing its value as a standardized foundation for AI-driven target identification. In a related move, Insilico recently entered into a strategic collaboration with Tigermed. The agreement will see both parties engage in long-term cooperation centered on clinical research for innovative drug products. Tigermed will leverage its full-service clinical research capabilities to provide Insilico with tailored, end-to-end support covering key areas such as clinical monitoring, data management and statistical analysis, medical affairs, pharmacovigilance, and regulatory affairs. A dedicated team will be established to design service solutions aligned with Insilico's AI-driven R&D approach. The partnership represents a combination of strengths in AI technology and clinical development innovation.